LAS VEGAS, NV. 28 May, 2015 — Euphoria Wellness rolled out the welcome mat for Nevada’s first cannabis testing company, DigiPath Labs, today with the announcement of a one year deal between the two companies.
Cannabis testing finally kicked off in Nevada yesterday, after months of bureaucratic limbo, with state officials deliberating over pesticide and contamination standards. Euphoria Wellness, expected to be the first cannabis dispensary to open in Las Vegas, will have comprehensive safety and potency tests conducted on its products by DigiPath.
Todd Denkin, president of DigiPath Labs, said in a press statement, “DigiPath Labs will analyze samples of products sold by Euphoria Wellness for unsafe levels of contaminants such as heavy metals, microbes, mycotoxins, pesticides, and solvents, which can exacerbate patient health issues. We will also quantify cannabinoid and terpenoid levels and deliver detailed reports that Euphoria’s staff can use to help patients.”
DigiPath Labs is now providing a full range of marijuana analysis at its Las Vegas laboratory under the direction of Cindy Orser, PhD. In a recent press release Orsner said, “Cannabis contains hundreds of different medicinal compounds—each effective for treating specific medical conditions—and we haven’t adopted a standardized way of growing it. Testing cannabis products for unhealthy levels of contaminants and medicinal potency is the only way to ensure product safety and potential efficacy.”
DigiPath Labs, a subsidiary of DigiPath, Inc. (OTCQB: DIGP, temporarily changed to: DIGPD) offers cannabis growers and marijuana-based product-makers advanced scientific testing using state of the art analytical instrumentation at their flagship facility.
The commencement of scientific testing has been welcomed by Nevada dispensaries that could not open for business until they could test their products in order to meet state compliance requirements.